{
  "nctrialId": "HC-1542",
  "title": "A  Open-Label, Placebo-Controlled  Study of PRO-108 (androgen receptor antagonist) in Patients With Heart Failure",
  "officialTitle": "A  Open-Label, Placebo-Controlled  Study of PRO-108 (androgen receptor antagonist) in Patients With Heart Failure",
  "sponsor": "Vancouver Coastal Health Research Institute",
  "indication": "Heart Failure",
  "phase": "Phase 2",
  "fileName": "HC-1542.json",
  "fileSize": 226722,
  "date": "2024-02-11",
  "completionDate": "2027-10-30",
  "drugName": "PRO-108 (androgen receptor antagonist)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a  open-label, placebo-controlled  study designed to evaluate the efficacy and safety of PRO-108 (androgen receptor antagonist) in patients with Heart Failure. The study will enroll approximately 219 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 19-76 years\n- Confirmed diagnosis of Heart Failure\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}